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Abstract
Even though fertility is reduced, conception and delivery are possible in all stages of CKD. While successful planned pregnan-
cies are increasing, an unwanted pregnancy may have long-lasting deleterious effects, hence the importance of birth control, 
an issue often disregarded in clinical practice. The evidence summarized in this position statement is mainly derived from the 
overall population, or other patient categories, in the lack of guidelines specifically addressed to CKD. Oestroprogestagents 
can be used in early, non-proteinuric CKD, excluding SLE and immunologic disorders, at high risk of thromboembolism and 
hypertension. Conversely, progestin only is generally safe and its main side effect is intramestrual spotting. Non-medicated 
intrauterine devices are a good alternative; their use needs to be carefully evaluated in patients at a high risk of pelvic infec-
tion, even though the degree of risk remains controversial. Barrier methods, relatively efficacious when correctly used, have 
few risks, and condoms are the only contraceptives that protect against sexually transmitted diseases. Surgical sterilization is 
rarely used also because of the risks surgery involves; it is not definitely contraindicated, and may be considered in selected 
cases. Emergency contraception with high-dose progestins or intrauterine devices is not contraindicated but should be avoided 
whenever possible, even if far preferable to abortion. Surgical abortion is invasive, but experience with medical abortion in 
CKD is still limited, especially in the late stages of the disease. In summary, personalized contraception is feasible, safe and 
should be offered to all CKD women of childbearing age who do not want to get pregnant.
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Introduction
Chronic kidney disease (CKD) is usually cited as a cause 
of reduced fertility, but in fact this simplistic assumption is 
probably true only for the last stages of the disease, or for 
some immunologic diseases, of which systemic lupus ery-
thematosus (SLE) can be considered the prototype [1–4].
Almost paradoxically, we have more information on 
fertility and pregnancy rates in the late stages of kidney 
disease, mainly because CKD is known and acknowledged, 
than in the early CKD stages, in which a significant num-
ber of women, perhaps even the majority, do not realize 
they are affected by CKD, or do not consider that this is 
relevant in determining pregnancy outcomes [1, 5–7].
While several recent studies have been addressed to 
women with CKD and their desire, still too often frus-
trated, to give birth, contraception is not a part of the rou-
tine work-up for CKD patients, notwithstanding the fact 
that, albeit with lower rates, pregnancy is possible in all 
CKD stages, including transplantation and dialysis [1, 2, 
8–12].
It is in particular in the late CKD stages that the wide-
spread idea that fertility is sharply reduced may cause 
doctors to overlook counselling on contraception, with 
potentially devastating clinical and psychological effects. 
Careful planning of pregnancy is vitally important in all 
disease stages, to avoid complications for mother (for 
example in the case of active immunologic diseases) and 
foetus (for example exposure to potentially teratogenic 
drugs) [13–16].
Some recent reviews have addressed the issue of contra-
ception in CKD; they all acknowledge the lack of detailed, 
specific evidence deriving from primary studies on CKD 
women [17–21]. The high heterogeneity of CKD stages, 
type of disease and treatment is one of the reasons for this 
lack of evidence or of the use of low-quality evidence, 
even in the fields most often studied (kidney transplan-
tation, lupus nephropathy and diabetic nephropathy) 
[20–23].
With this in mind, the Italian Society of Nephrology’s 
Project Group on Kidney and Pregnancy has undertaken 
the preparation of the present best practice statement. We 
will try to summarize the available evidence and provide 
answers to open questions on contraception in CKD inte-
grating the currently available “best practice” statements 
on pregnancy in CKD, dialysis, kidney transplantation and 
follow-up after preeclampsia [24–27].
Our review will first discuss the main modes of contra-
ception available for the general population, and then try to 
contextualize them in the various stages of CKD, in dialysis 
and after kidney transplantation, with particular regard to the 
potential interaction between contraceptives and the pharma-
cologic treatments most commonly used in CKD.
World Health Organization (WHO) criteria 
for election of contraception
Analogously to its classification of drug teratogenicity, the 
World Health Organization (WHO) provides a general score 
for supporting contraceptive eligibility in different diseases 
(Table 1) [28]. The safety of every contraceptive is clas-
sified in one of four categories: in categories 1-2 the use 
of the contraceptives is with no or minimal restriction, in 
categories 3 and 4, WHO advises avoidance, (the strength 
of recommendations varies in and motivated exceptions are 
proposed in category 3).
The evidence on which WHO criteria were based came 
from studies on a wide range of diseases and conditions, 
among them diabetes, hypertension, SLE and kidney 
transplantation. Chronic kidney disease was, however, not 
included.
WHO’s Medical Eligibility Criteria (MEC) for contra-
ception are based on two complementary considerations 
regarding safety: first, the effect the contraceptive has on 
the disease (worsening or increasing risk); second, the effect 
the disease has on the efficacy of the contraceptive method.
WHO’s most recent classification considers the following 
contraceptive methods:
• Combined hormonal contraceptives (CHC)
• low dose (≤ 35 mcg Ethinyl Estradiol) combined oral 
contraceptives (COCs).
• Combined patch (P).
• Combined vaginal rings (CVR).
Table 1  Medical Eligibility Criteria (MEC) for contraceptive use (WHO 2015) [28]
MEC Medical Eligibility Criteria, WHO World Health Organization
MEC categories for contraceptive eligibility
1 A condition for which there is no restriction for the use of the contraceptive method
2 A condition where the advantages of using the method generally outweigh the theoretical or proven risks
3 A condition where the theoretical or proven risks usually outweigh the advantages of using the method
4 A condition which represents an unacceptable health risk if the contraceptive method is used
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• Combined injectable contraceptives (CICs) *.
• Progestin-only pills (POPs).
• Depot-medroxyprogesterone acetate (DMPA)*.
• Norethisterone enanthate (NET-EN)*.
• Levonorgestrel (LNG)* and Etonogestrel (ETG) 
implants.
• Emergency contraceptive pills (ECPs).
• Copper-bearing intrauterine devices (Cu-IUDs).
• Levonorgestrel-releasing IUDs (LNG-IUDs).
• Copper-IUDs for emergency contraception (E-IUD).
• Progesterone-releasing vaginal rings (PVR)*.
• Barrier methods (BARR).
• Fertility awareness-based methods (FAB).
• Lactational amenorrhoea method (LAM).
• Coitus interruptus (CI).
• Female and male sterilization (STER).
*Not available in Italy.
In our review we use WHO’s categories of contracep-
tive methods and their specific Medical Eligibility Criteria 
(MEC). Obviously, as is emphasized in the MEC, counsel-
ling must be personalized and consider individual charac-
teristics and risk factors; those generally listed include age, 
breastfeeding status, dyslipidaemia, severe cardiovascular 
disease, migraine, severe liver disease, concomitant thera-
pies and body mass index. Kidney diseases are not specifi-
cally considered, hence the need for the present best practice 
statement.
Efficacy of contraceptive methods
The efficacy of a contraceptive method is conventionally 
measured by the Pearl Index, i.e. the number of pregnancies 
in 100 women using the method for 1 year (1300 periods). 
The lower the number, the more effective the method is. It 
should be noted that to some extent the Pearl Index depends 
on the user population’s characteristics, training in correct 
use of the method and the fertility of the couples included.
A recent US review proposes a classification of contra-
ceptive effectiveness stratified for “optimal use” or “typi-
cal use” (taking inaccuracies into account); it also analyses 
adherence to methods after 1 year of use. Apart from surgi-
cal methods (which are obviously definitive), compliance 
is high for implants and IUDs, which can remain in place 
for 3–5 years, but adherence to combined hormonal con-
traceptives was as low as 67%. Barrier methods are quite 
effective with “perfect” use, but typical use produces a high 
percentage of unintended pregnancies; the same applies to 
withdrawal and ovulation methods (Table 2) [29].
There are also differences between countries regarding 
availability and choice of contraceptives. For example, in 
Italy CICs are not available and implants are rarely used. 
Male sterilization is rare, as in the rest of the world; male 
condom use and withdrawal are widely used, with conse-
quences linked to poor efficacy (Table 3) [30].
Table 2  Percentage of failure of the main contraceptive methods and 
percentage of women continuing the method at 1 year. Adapted from 
(Trussell 2007) [29]
IUD intrauterine device, COC combined oral contraceptive, POP pro-
gestin-only pill, LNG-IUD levonorgestrel intrauterine device
Method % of women experiencing 
an unintended pregnancy 
within the first year of use
% of women 
continuing use at 
1 year
Typical use Perfect use
No method 85 85 –
Non-pharmacological methods
 Female condom 21 5 41
 Withdrawal 20 4 46
 Diaphragm 17 16 57
 Ovulation method 23 3
 Male condom 13 2 43
 Copper IUD 0.8 0.6 78
Pharmacological methods
 COCs and POPs 7 0.3 67
 Patch 7 0.3 67
 Vaginal ring 7 0.3 67
 Injectable 4 0.2 56
 LNG-IUD 0.1–0.2 0.1–0.2 80
 Implant 0.1 0.1 89
Surgical methods
 Tubal occlusion 0.5 0.5 100
 Vasectomy 0.15 0.1 100
Table 3  Percentage of couples in fertile age that chose a specific con-
traceptive method in 2018. Adapted from the Population Reference 
Bureau, 2019 [30]
IUD intrauterine device
Method World Europe Italy Devel-
oping 
countries
All methods 62 70 65.1 54
Non-pharmacological methods
 IUD 13 11 4.8 13
 Condom 8 21 20.9 6
 Withdrawal 4 2 17.5 3
Pharmacological methods
 Oral contraceptives 9 20 20.3 8
Surgical methods
 Male sterilization – – – –
 Female sterilization 18 22 5.8 20
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Design of the best practice position 
statement
The present best statement has been designed, in collabo-
ration with obstetric teams with experience in the manage-
ment of kidney patients, to support clinical nephrologists 
with practical indications on the most commonly used 
birth control methods and treatments, with the final aim 
of giving nephrologists the tools they need to actively par-
ticipate in the choice of a contraceptive agent, in keeping 
with obstetric indications and patient preferences.
It is organized according to type and efficacy of contra-
ceptive agents, trying to identify, for each of them, the limits 
and the specific indications or contraindications in different 
categories of CKD patients. The evidence related to CKD is 
low, and the indications and suggestions given are based on 
similar diseases (immunologic diseases), on CKD complica-
tions (hypertension) or on the presence of related diseases, 
such as diabetes. Within these limits, we have tried to sum-
marize a counselling policy suitable for women in different 
phases of CKD, dialysis and transplantation.
Combined hormonal contraceptives 
(aestro‑progestinic agents agents)
– Combined hormonal contraceptives (CHCs) are widely 
used and highly effective, but the cardiovascular and 
thrombotic risks are high and this can be of particular 
relevance for CKD patients (grade of evidence: high for 
the general population, low for the specific categories 
related to CKD patients).
– There is no absolute contraindication for CHC use in 
CKD patients without hypertension or immunologic 
diseases or those taking immunosuppressive drugs 
(grade of evidence: low for the specific categories 
related to CKD patients).
– No correlation between CHC and neoplastic risk has 
been established. An increase in incidence of breast 
and cervical cancer is debated; likewise, the protective 
effect on ovarian, endometrial and colorectal cancer is 
controversial (grade of evidence: debated in relation to 
the general population, no studies on CKD patients).
– CHC can induce or worsen albuminuria; this side effect 
is usually reversible at discontinuation in patients with-
out CKD. The pathogenesis is not known but seems to 
be independent from blood pressure (grade of evidence: 
high for the general population, no studies on CKD 
patients)
– The use of a patch is associated with higher circulat-
ing hormonal levels, with consequently higher risk of 
adverse effects (grade of evidence: high for the general 
population, low for the specific categories related to 
CKD patients).
– Vaginitis and leucorrhoea are more frequent with a vagi-
nal ring and a ring may favour urinary tract infections 
(grade of evidence: high for the general population, low 
for the specific categories related to CKD patients).
– Alternatives should be systematically sought in advanced 
and progressive CKD, immunologic diseases, and com-
plicated kidney transplantation; the presence of proteinu-
ria and hypertension increases the risk of adverse effects 
(grade of evidence: low for the specific categories related 
to CKD patients, but supported by shared clinical views).
Combined hormonal contraceptives are contraceptives 
that contain different types of oestrogen and progestin, com-
bined in different dosages. They are the first, and still the 
most widely used contraceptives, colloquially referred to as 
“the pill”. They are highly effective (Pearl Index < 1 with 
perfect use, see Table 2). Combined hormonal contracep-
tives exist in four forms: oral contraceptives (COCs), trans-
dermal patch (P), transvaginal ring (CVR) and combined 
injectable contraceptives (CICs).
Besides being used for birth control, combined hormo-
nal oral contraceptives are routinely prescribed to non-CKD 
patients for dysmenorrhea (painful menstruation), functional 
ovarian cysts, hypermenorrhea (abundant menstruation), 
polymenorrhea (frequent menstruation), endometriosis or 
acne.
The Medical Eligibility Criteria take very few nephropa-
thies into account: diabetic nephropathy in category 3 or 
4 (depending on severity), while diabetes without vascular 
disease is included in category 2; when normotensive, well 
controlled and in remission, SLE is also included in cat-
egory 2 but the presence of antiphospholipid antibodies war-
rants its inclusion in category 4 (absolute contraindication). 
Kidney transplantation is categorized in more than one way 
(category 2 if “non- complicated”, up to 4 in the presence 
of organ failure or acute/chronic rejection). Hypertension, 
which often coexists in kidney disease, is in category 3, even 
when moderate and controlled by therapy. [28]
Combined oral contraceptives (COCs) or “the pill”, are 
one of the most effective contraceptive methods (failure 
rate with perfect use: 0.3%, Table 2) and are widely used 
throughout the world. Birth control pills contain different 
types of two hormonal components, progestin and oestro-
gen, combined in different dosages. COCs inhibit the release 
of GnRH, thus blocking the release of the hypophysis hor-
mones that stimulate ovulation, alter the endometrium 
and cause thickening of the cervical mucus. Birth control 
pills must be taken for between 21 and 24 days per month, 
with 4–7 days of pause between cycles, in which a suspen-
sion bleeding appears. Some COCs have the same dosage 
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during the entire month (monophasic pills), others have dif-
ferent dosages (multiphasic pills), in order to better mimic 
natural hormonal fluctuations. The oestrogen typically 
associated with progestin is Ethinyl Estradiol (EE), with 
a dosage that varies from 10 to 35 mcg/day (“low-dosage 
oestrogens” < 35 mcg/day). New oestrogen-derivatives have 
recently been introduced (Estrogen Valerate, Estradiol) to 
minimize the oestrogen-related adverse effects of taking 
birth control pills, since they induce less liver protein syn-
thesis (e.g. sex-hormone binding globulin, angiotensinogen 
and coagulation factors) (Table 4).
The first generation of contraceptive pills, developed 
in the 1960s, used a high concentration of oestrogen with 
progestin with androgenic activity; the second generation 
of hormonal contraceptives combined lower levels of oes-
trogens with various testosterone-derived progestins char-
acterized by low but significant androgenic activity; the 
most widely used progestin in this category is Levonorg-
estrel (LNG). COCs in combination with Levonorgestrel 
have the lowest thromboembolic risk (Tables 5, 6) [31], 
but their androgenic effects must be considered before pre-
scribing them to women with acne or hirsutism. Since the 
1990s, further combined hormonal contraceptives have been 
developed, with different progestins; these are sometimes 
referred to as third-generation (those containing Desogestrel, 
Gestodene or Norgestimate) and fourth-generation contra-
ceptives (those containing Norelgestromine, Etonogestrel, 
Drospirenone or Dienogest). The classification in different 
“generations”, however, is not standardized, and may differ 
between publications, thus making it advisable to refer to the 
specific contents and not merely to a “generation”.
The transdermal CHC or combined patch (P) is a 4.6-
cm2 patch that must be replaced every week, for three con-
secutive weeks, followed by a patch-free week. The active 
principles contained in a single patch are Ethinyl Estradiol 
(6 mg) and Norelgestromin (600 mcg), releasing on average 
34 mcg/day of Ethinyl Estradiol and 203 mcg/day of Norel-
gestromin. Efficacy and cycle control are similar to those of 
COCs, but the patch has the advantage of avoiding first-pass 
effect in the liver. The circulating levels of oestrogen are 
usually higher in transdermal than in oral CHCs.
The combined vaginal ring (CVR), manufactured from 
ethylene-co-vinyl acetate, is a flexible atoxic ring measuring 
5.4 cm in diameter that contains Etonogestrel (11.7 mg) and 
Ethinyl Estradiol (2.7 mg), releasing on average 120 mcg/
day of Etonogestrel and 15 mcg/day of Ethinyl Estradiol. 
The ring is kept in the vagina for 3 consecutive weeks, and 
is replaced after 1 ring-free week. Efficacy and control of 
the cycle are optimal, and the principles are not subject to 
first pass effect in the liver. Moreover, the oestrogen dose 
is very low.
The recently developed injectable CHCs (combined 
injectable contraceptives) contain either 25 mg of Depot-
medroxyprogesterone acetate and 5 mg of Estradiol Cipion 











Table 5  Risk of developing 
deep venous thrombosis in per 
year of use. Modified from the 
European Medicines Agency, 
2014 [31]
CHC combined hormonal contraceptive
a Further studies are ongoing or planned to collect more data
Hormonal contraceptive use
Combined hormonal contraceptives (CHCs)
Cases of deep 
venous thrombosis
No CHC (and not pregnant) 2/10,000 women
CHC containing Levonorgestrel, Norethisterone or Norgestimate 5–7/10,000 women
CHC containing Etonogestrel or Norelgestromin 6–12/10,000 women
CHC containing Drospirenone, Gestodene or Desogestrel 9–12/10,000 women
CHC containing Chlormadinone, Dienogest or Nomegestrol Not yet  knowna
Table 6  Odds ratios comparing the risk of non-fatal venous thrombo-
embolism in users of different contraceptives. Adapted from MEGA 
study [33]
OR odds ratio, CI confidence interval





Ciproterone acetate 6.8 4.7–10.0
Desogestrel 7.3 5.3–10.0
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or 50 mg of Norethisterone Enanthate and 5 mg of Estradiol 
Valerate. Combined injectable contraceptives have good 
pharmacokinetics and are less subject to individual varia-
tions, but can cause spotting and bleeding. Combined inject-
able contraceptives are currently not available in Italy and 
are mostly used in developing countries, because the therapy 
is easy to manage (one injection per month) and inexpensive.
Risks and side effects of CHCs
In spite of their high efficacy, CHCs are not devoid of side 
effects. Table 4 reports their main non-thromboembolic side 
effects.
Thromboembolic and cardiovascular events are rare, 
although potentially severe; the risk of venous thromboem-
bolism varies between CHCs, depending on the amount of 
oestrogen and type of progestin they contain, ranging from 
5 to 12 cases per 10,000 women, a two- to five-fold increase 
with respect to the usual incidence of 2 per 10,000 in women 
not using CHCs (Tables 5, 6) [31]. Overall, the risk is 
higher in the first year of use and is correlated with oestro-
gen dose. A meta-analysis published in 2018 analysed the 
risk of venous thrombosis associated with different types of 
combined oral contraceptives: the risk was lowest on COCs 
containing Levonorgestrel, followed by Gestodene and 
Cyproterone and highest on those containing Desogestrel 
(according to Oedingen, RR 1.46; 95% CI 1.33–1.59 [32]). 
However, many studies lack information on potential con-
founders such as family history, body mass index, smoking 
and, most importantly, duration of use [32–36].
The association between the use of oral contraceptives 
and hypertension has been known since 1967, but the patho-
genesis is still not fully clear. Genetic predisposition, dura-
tion of treatment, age and obesity are probably contribut-
ing factors. Oestrogens stimulate the hepatic synthesis of 
angiotensinogen, and activate the renin-aldosterone system; 
renal and peripheral hemodynamic alterations have been 
reported. Progestins can also increase blood pressure, albeit 
less significantly, probably via increased sodium retention; 
the effect seems to be of shorter duration, leading to the con-
clusion that progestin-only agents are less dangerous from 
this point of view [37–40].
A large body of evidence supports an increased risk 
of developing or worsening of albuminuria (OR 1.90; CI 
1.23–2.93, according to Monster 2001 [43]). The increase is 
usually modest and reversible after discontinuation of CHCs, 
but must be taken into consideration when a CHC is pre-
scribed to a CKD patient. The increase in urinary albumin 
excretion is modulated by age (increasing in older women) 
and type of oestrogen; it tends to be higher on second- or 
third-generation CHCs. The pathogenesis is not fully known, 
but may be related to a haemodynamic effect. This side effect 
underlines the fact that CHCs’ long-term effects on kidney 
function are not fully understood. Although there is cur-
rently no evidence of a CHC-related predisposition to renal 
disease, some authors suggest that CHCs may represent a 
“first hit” in the development of CKD. In case of prescrip-
tion of CHCs to patients with a kidney ailment, it is advis-
able to carry out periodic controls of proteinuria [40–45].
Drospirenone and the other fourth-generation progestins 
sometimes increase potassium levels because of their anti-
mineralocorticoid effects, and should be used with care in 
patients with electrolyte disturbances [46].
The evidence of CHCs posing a cancer risk is controver-
sial, as studies are highly heterogeneous in terms of popula-
tion characteristics, type of the contraceptive, and duration 
of assumption. Furthermore, the long-term studies we have 
regard mainly first-generation, high-dosage pills, and the 
long-term effects of the more recent formulations are not 
yet known.
Several epidemiological studies and a systematic review 
published in 2003 reported an association between HPV-
related cervical cancer and use of COCs; the data was not 
confirmed in a recent meta-analysis, suggesting that this 
association is related to the fact that condoms are seldom 
used in patients on CHCs, with a consequent higher inci-
dence of HPV infections [47–56].
An increase in breast cancer is controversial; some data 
suggest a slight but significant increase in women using 
COCs (Gierisch 2013: OR 1.08; 95% CI 1.00–1.17 [56]), 
most frequently in triple-negative forms. The incidence of 
breast cancer decreases 5–10 years after a woman stops tak-
ing birth control pills [49, 56–69].
Conversely, the incidence of some cancers is significantly 
reduced by oral contraceptive use, regardless of the duration 
of therapy. This holds true for colorectal cancer (see Gierisch 
2013: OR 0.86; CI 0.79–0.95 [56]) and endometrial cancer 
(see Gierisch 2013: OR 0.57; CI 0.43–0.77 [56]). CHCs 
are also associated with benign hepatic tumours, including 
hepatic adenomas or focal nodular hyperplasia, which rarely 
turn into a malignant hepato-cellular carcinoma. Further-
more, COC users, whether they are without predisposing 
factors or are carriers of BRCA1/BRCA2, apparently have a 
reduced risk of ovarian epithelial cancer [49, 56, 57, 70–79].
In summary, CHCs seem to protect against some types of 
cancers and to increase the risk of developing others. Since 
quantifying this risk is extremely difficult, the risk balance 
could be considered neutral and the decision on whether or 
not to prescribe this type of contraceptive should be based 
on other considerations. The only exception, according to 
WHO, is the presence or history of breast cancer.
The side effects of taking CHCs could be expected 
to be similar in their transdermal, vaginal and oral for-
mulations; however, a Cochrane review published in 
2013 [80] showed that patch users have a higher rate 
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of discontinuation than oral contraceptive users, due to 
adverse effects including breast discomfort, dysmenorrhea, 
nausea and vomiting, and local irritation. Ring users also 
reported less nausea, acne, irritability, depression, and 
emotional problems than COC users. The main complaints 
recorded with the transvaginal ring include vaginitis (OR 
2.48; CI 1.39–4.43 with respect to oral agents [80]) and 
leucorrhoea (OR 3.21; CI 1.61–6.40 [80]), but less vaginal 
dryness. These effects may be of particular relevance in 
immunosuppressed patients or in patients with frequent 
urinary tract infections [80].
A potential favourable aspect is the fact that transder-
mal and vaginal preparations do not undergo first pass liver 
metabolism; therefore, they have a lower risk of poten-
tially dangerous pharmacologic interferences involving the 
cytochrome P4503A4. This is particularly important in the 
case of calcineurin inhibitors, metabolized by the same path-
way. In fact CHCs and progestin-only contraceptives have an 
inhibitory effect on P4503A4, thus increasing the concen-
tration of calcineurin inhibitors, in particular Cyclosporine. 
Conversely, calcineurin inhibitors (in particular Tacrolimus) 
have an inductive effect on P4503A4, potentially reducing 
contraceptive efficacy [81–83].
Progestin-only contraceptives (POPs, injectables, 
implants)
Progestin-only contraceptives represent an effective alter-
native to CHCs, mainly due to a better cardiovascular profile 
(grade of evidence: high for the general population, low for 
the specific categories related to CKD patients).
There is no absolute contraindication for progestin-only 
contraceptive use in CKD patients (grade of evidence: high 
for the general population, low for the specific categories 
related to CKD patients).
Weight gain is a potential side effect (grade of evidence: 
high for the general population, low for the specific catego-
ries related to CKD patients).
Potential interference with liver metabolism should be 
considered in cases of calcineurin inhibitors (grade of evi-
dence: high for the general population, low for the specific 
categories related to CKD patients).
Progestin-only contraceptives act through inhibition of 
the release of GnRH, by modifying the composition of the 
cervical mucus making it impenetrable, and by reducing 
endometrial thickness, impairing implantation, and affect-
ing tubal motility. The main advantage of progestin-only 
contraceptives lies in their minimal (or absent) impact on 
coagulation and blood pressure, thus making them good 
alternatives in women in a WHO MEC category 3 or 4 for 
combined hormonal contraceptives, which is the case for 
many women with CKD. Furthermore, these agents can be 
used postpartum and during lactation. However, although 
usually mild, weight gain can be an important drawback, 
in particular for obese and overweight patients [29, 84–88].
The contraindications and warnings identified by WHO 
are generally mild: category 1–2 hypertension; SLE 2, 
and SLE 3, in the presence of anti-phospholipid antibod-
ies (Tables 7, 8). Kidney transplantation is rated 2, inde-
pendently from the presence of hypertension, proteinuria 
or functional reduction. Diabetes-related nephropathy is 
rated 2 regarding progestin-only pills or implants, and rated 
3 with respect to injectable progestins [31]. Several differ-
ent approaches are available: POPs (progestin-only pillx or 
“minipillx”); and the depot method, either via intramuscular 
administration or a subdermal implant.
POP therapy available in Italy consists of Desogestrel 
(75 mcg/day) that must be taken every day, without inter-
ruptions; elsewhere in Europe and in other settings, the most 
widely used minipills contain Desogestrel (as in Italy) or 
Norethisterone (350 mcg/day); Norethisterone is the only 
POP available in the United States. The failure rate with 
perfect use is similar to COCs’, but the absence of oestrogens 
reduces control of the cycle, potentially causing spotting 
Table 7  WHO indications 
regarding hypertension and 
diseases of nephrological 
interest
WHO World Health Organization, SLE systemic lupus erytematosus, CHC combined hormonal contracep-
tive, POP progestin-only pill, Cu-IUD copper-bearing intrauterine device, LNG-IUD levonorgestrel intrau-
terine device
a Cat.2 implant
b Cat. 3 injectable
Disease POPs, implants, 
injectable
Cu-IUD LNG-IUD
Adequately controlled hypertension 1a 1 1
Diabetic nephropaty 2b 1 2
SLE 2 1 2
SLE + positive antiphospholipid antibodies 3 1 3
Uncomplicated kidney transplantation 2 2 2
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or irregular menses; moreover, ingestion must be regular 
to reduce the risk of unintended pregnancies (Pearl Index, 
referred to typical use, is 1–5, see Table 2).
POPs undergo first pass liver metabolism, potentially 
interacting with calcineurin inhibitors [82, 83].
Thanks to their safer cardiovascular profile, POPs are 
not contraindicated in dialysis patients; however, spotting 
may be bothersome in the case of heparin administration in 
dialysis. Conversely, since they reduce menstrual bleeding 
(or interrupt menses), they can be useful in patients with 
intense bleeding.
The thrombotic risk in patients taking a progestin-only 
contraceptive is debated. A Mexican trial [89] compared 
adverse effects in three group of 54 patients each, one group 
using COCs, one POPs, and one IUDs: four patients with 
systemic lupus erythematosus had thromboses while receiv-
ing hormones (two patients with COCs, two patients with 
POPs). On this basis, the contraceptive guidelines suggest 
caution in POP use in patients with systemic lupus ery-
thematosus or nephrological complications: WHO puts 
progestin-only contraceptives in category 2 or 3. In recent 
years, the evidence has been reassuring, suggesting a low 
thrombosis risk, and this contraceptive is being more widely 
used. The RCOG guidelines now state that “The available 
evidence does not demonstrate an increased risk associated 
with POPs” [89–93].
A meta-analysis showed that the risk of thromboem-
bolism in women using a low-dosage progestin-only con-
traceptive is comparable to that of non-users (RR 1.03, CI 
95% 0.76–1.39 according to Mantha 2012 [94]) and does 
not increase even in women at high thromboembolic risk. 
Evidence on women with rheumatic diseases is lacking, and 
positions are different: WHO does not recommend use by 
patients with antiphospholipid antibodies (category 3), while 
RCOG considers progestin-only contraceptives a safe alter-
native to CHCs for patients with SLE, active nephritis and 
vascular diseases [90, 94].
In a recent review on contraception in patients with 
rheumatic diseases, Sammaritano concludes that proges-
tin-only contraceptives are generally safe and that “the 
risks associated with any hormonal contraceptive method 
must be balanced with the risks of unintended pregnancy” 
[95].
Progestin-only subdermal implants (Etonogestrel or 
Levonorgestrel) are a fairly long-term (3 years), revers-
ible and relatively safe method, with a failure rate of 0.1% 
(see Table 2). Their main adverse side effect is irregular 
menstrual bleeding or amenorrhea, as with POPs. WHO 
cautions against their use by patients with cardiovascular 
diseases or diabetes, mainly because of the risk of weight 
gain (although this is debated and weight gain is usually 
small). Implants can cause a reduction in bone mineral 
density, albeit less than those caused by other long-acting 
formulations (DMPA) [85, 96–102].
There are other injectable progestin-only therapies 
widely used as contraceptives. Two molecules are avail-
able: Depot-medroxy-progesterone acetate (DMPA) and 
Norethisterone Enanthate (NET-EN). Both highly effec-
tive, they differ in frequency of administration. Women 
taking DMPA are more likely to develop amenorrhoea, but 
there are no differences regarding other side effects. The 
injection of DMPA (150 mg) is used mostly in developing 
countries, because the injection is expensive (less than 1 
dollar) and its effect lasts for 3 months. DMPA is available 
in Italy, but is only registered for use in treating endome-
trial and breast cancers. DMPA can reduce bone mineral 
density and this side effect can be relevant in patients on 
long-term steroid treatment, but the reduction tends to be 
reversible on discontinuation. Norethisterone Enanthate 
(NET-EN, dosage 200 mg), the other available injectable 
progestin-only contraceptive, has a duration of action of 
2 months [103].
Table 8  Indications on contraception for SLE patients. Adapted from references [28, 95, 106]
CHC combined hormonal contraceptive, POP progestin-only pill, LNG-IUD levonorgestrel-intrauterine device, SLE systemic lupus erythemato-
sus, aPL antiphospholipid antibodies, WHO World Health Organization, EULAR the European League Against Rheumatism
CHCs POPs LNG-IUD
SLE
 WHO 2 2 2
 EULAR Can be considered Not available Can be offered to all patients
 SAMMARITANO No increased flare in stable patients No risk flare No risk flare
SLE + aPL
 WHO 4 3 3
 EULAR controindicated Carefully weighed against the risk 
of thrombosis (2B)
Can be offered to all patients
 SAMMARITANO Increased risk thrombosis. AVOID No risk thrombosis No risk thrombosis
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Intrauterine devices (IUD)
– Medicated or non-medicated intrauterine devices are 
efficacious contraceptive alternatives in CKD patients 
(grade of evidence: high for the general population, low 
for the specific categories related to CKD patients).
– Intrauterine devices are associated with a slightly 
higher risk of pelvic infections in the first 20 days after 
placement, and their use is restricted in patients with 
malformations or pyelonephritis, and in those on peri-
toneal dialysis. Attention must be paid to the placement 
procedure (grade of evidence: high for the general pop-
ulation, low for the specific categories related to CKD 
patients).
– The main advantage of the non-medicated copper-only 
IUD is the avoidance of drug interactions; LNG-IUD has 
the advantage of reducing the amount of menstrual blood 
loss (grade of evidence: high for the general population, 
low for the specific categories related to CKD patients).
– Extrauterine pregnancies appear to be more frequent 
in women using IUDs (grade of evidence: high for 
the general population, low for the specific categories 
related to CKD patients).
IUDs (intrauterine devices, also called “coils”) are small, 
T-shaped, flexible devices that are inserted in the uterus; 
they stay in place for 3, 5 or 10 years, depending on the total 
surface occupied by the copper and on the dosage of the 
progestin released, but can easily be removed before term if 
complications arise or a woman wishes to conceive.
Two main types of IUDs are available: the copper-only 
IUD (5–10 years of efficacy, according to type), that do not 
contain any active drugs, and a medicated form, contain-
ing long-acting progesterone (Levonorgestrel, LNG-IUD, 
which has 3–5 years of efficacy).
The copper-only IUDs release copper ions, which are 
toxic to sperm; moreover, they induce local modifications 
of the endometrium and cervical mucus that prevent fer-
tilization. The medicated forms release a small dose of 
Levonorgestrel (14–20 mcg/day) that thickens the cervi-
cal mucus, preventing the movement of spermatozoa. To a 
lesser degree, they can also impair ovulation. Their place-
ment in primiparas and multiparas is easy because the cervix 
is already dilated, while in nulliparas it can be more com-
plicated, in particular for the older forms; recent data show 
that the placement may be easy also in nulliparous women 
with a minimal discomfort [103]. Placement in patients with 
previous caesarean section requires caution (for example, 
ultrasound-guided placement). Placement can sometimes be 
painful, but the procedure is fast [104].  A copper-bearing 
IUD can also be inserted as an emergency contraceptive 
method within 120 h from unprotected sexual intercourse 
[105].
The IUD is a very effective method, with a low risk of 
failure (0.1–0.6%, Table 3). Since it is a long-term contra-
ceptive method, compliance is very high. Its greatest advan-
tage is probably that it makes it possible to avoid using active 
drugs, a safer choice in diseases associated with thromboem-
bolic risk, risk of hypertension and weight gain.
According to WHO indications, the copper-bearing IUD 
can be safely used in patients with hypertension, diabe-
tes with nephropathy, deep thromboembolism, and lupus. 
Antiphospholipid antibodies are instead a contraindication 
for the use of a medicated IUD [29].
The thrombotic risk of LNG-IUDs, given their progestin 
content, has been debated, but the evidence shows that the 
risk is low. A meta-analysis by Mantha et al. showed that the 
LNG-IUD was not associated with a higher thrombotic risk 
(RR 0.61, CI 95% 0.24–1.53) [94]. Sammaritano concluded 
that LNG-IUDs are safe and effective even in patients with 
rheumatic diseases [95]. According to EULAR (the Euro-
pean League Against Rheumatism), LNG-containing IUDs 
should be considered only if the benefits of the released hor-
mone outweigh the risk of thrombosis”. RCOG states that 
there is little or no increased risk of VTE associated with the 
use of an LNG-IUD [94, 95, 106, 107].
IUDs are associated with a higher risk of extrauterine 
pregnancy, an event that, however, has a very low cumula-
tive incidence and seems to have been associated with the 
first generation of IUDs. The risk is about 6 times higher 
than in the overall pregnant population and also exists in 
cases of previous use (OR 1.7% CI 95% 1.39–2.13, accord-
ing to Li [108]) and above all in cases of IUD failure (OR 
16.43%, 95% CI 10.42–25.89, according to Li [108]; 3.99 
(95% CI 2.06–7.72 according to Gaskins [109]). Two rare 
adverse effects are perforation of the uterus, related to the 
insertion procedure, and expulsion of the device. Commonly, 
the copper-bearing IUD induces a small increase in duration 
of menstruation and blood loss, while the LNG-IUD often 
reduces the flow and sometimes induces amenorrhea, and 
may therefore be useful in patients with anaemia [108–114].
The risk of infection related to IUDs is a matter of ongo-
ing debate. The timing of the increased risk is interesting: 
in a large retrospective study, cited in the RCOG guidelines, 
the overall risk of PID was 0.54% (95% CI 0.48–0.60) within 
90 days after placement; according to a review of 13 tri-
als, the risk of contracting a pelvic inflammatory disease is 
generally higher in the 20 days following IUD placement, 
suggesting that most infections are associated with the place-
ment procedure. This means that many could therefore be 
avoided by a combination of pre-placement identification 
of infections (bacteriologic testing), providing treatment if 
infections are found, and careful asepsis and/or antibiotic 
prophylaxis. After this time, the risk remains low unless 
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there is exposure to sexually-transmitted infections. It is not 
clear if the risk of infection is lower with LNG-IUDs than 
Cu-IUDs: one trial reported that the cumulative rate of PID 
was lower in women using LNG-IUDs compared to women 
using Cu-IUDs (cumulative discontinuation rates caused by 
PID for Cu-IUD 2.0 versus LNG-IUD 0.5, p < 0.013). How-
ever, in another study, PID rates did not differ between the 
two methods (termination rate because of PID: 0.7 for both 
Cu-IUDs and LNG-IUDs) [106, 115–118].
Regarding kidney transplantation, intrauterine devices 
are rated in category 3 for initiation of contraception, 2 for 
continuation [28]. Their placement in category 3 is probably 
related to occasional failure reports, but there is no evidence 
of an increase in risk of infections. IUDs are historically 
contraindicated in immunosuppressed women, since the 
IUD elicits a local inflammation that could be inhibited by 
immunosuppressive therapy. However, recent data do not 
confirm this finding, as they suggest that local inflammation 
induced by IUD involves macrophages, whereas iatrogenic 
immunosuppression involves lymphocytes; the few studies 
addressed to this question failed to find a significant differ-
ence in IUD failure between patients on immunosuppressive 
drugs and healthy women. There are no data regarding the 
risk of infection in transplanted patients, but no increase 
in the rate of infection has been found in immunocompro-
mised HIV positive women using IUDs. It is against this 
background that the US Center for Disease Control and Pre-
vention’s Medical Eligibility Criteria (CDC-MEC) for 2016 
supports the use of the IUD only following uncomplicated 
kidney transplantation. The CDC MEC warns that the risks 
may outweigh the benefits for complicated transplants [28, 
119, 120].
Barrier methods
– Barrier methods include condoms, diaphragms, cervi-
cal caps and sponges. Their main drawback is their low 
efficacy, often linked to errors in use (grade of evidence: 
high for the general population, low for the specific cat-
egories related to CKD patients).
– The barrier methods that contemplate the use of a sper-
micide, such as diaphragms or cervical caps, can increase 
the risk of urinary tract infections and should be used 
with care in immunosuppressed patients and in patients 
with urinary tract infections and/or malformations (grade 
of evidence: high for the general population, low for the 
specific category related to CKD patients).
– The main advantage of using barrier methods is their lack 
of side effects (grade of evidence: high for the general 
population, low for the specific categories related to CKD 
patients).
– The condom (male or female) is the only contraceptive 
method that protects against sexually transmitted diseases 
(grade of evidence: high for the general population, low 
for the specific categories related to CKD patients).
Barrier methods are contraceptives that function by pre-
venting direct contact between spermatozoa and an ovum. 
However, barrier methods are not as effective as other meth-
ods and cannot be considered an effective long-term con-
traceptive option, even if they are safe and do not interact 
with drugs. WHO does not pose any contraindications to 
their use [28].
The most widespread barrier method is the male con-
dom, but other barrier methods exist: the diaphragm (plus 
spermicide), the cervical cap (plus spermicide), the cervi-
cal sponge (not available in Italy) and the female condom 
(Table 9). The failure rate depends largely on correct posi-
tioning of the device and on the method itself. Spermicide 
use increases the risk of urinary tract infections, in particular 
those caused by Staphylococcus saprophyticus and E. coli; 
the pathogenesis is not completely understood, but it seems 
that spermicides may alter the vaginal environment, lead-
ing to a greater colonization by uropathogens. Care must 
therefore be taken if they are used by immunosuppressed 
patients or by patients with frequent urinary tract infections 
or malformations [121–127].
Emergency contraception
– Emergency contraception is based on a high dosage of 
progestin or placement of a copper-bearing IUD. The 
use of emergency contraception should be considered 
within 120 h after unprotected sexual intercourse (grade 
of evidence: high for the general population, low for the 
specific categories related to CKD patients).
– The main drawbacks are the risk of nausea and vomit-
ing and potential interaction with calcineurin inhibitors 
(grade of evidence: high for the general population, low 
for the specific categories related to CKD patients).
Emergency contraception is the term used for forms of 
contraception that are effective in preventing an unintended 
pregnancy when administered within a specified period of 
time after unprotected, or inefficaciously protected sexual 
intercourse. Emergency contraception can be achieved by 
administering orally a high dose of progestin or the selective 
progestin receptor modulator (in Italy the available formu-
lations are a single dose of 30 mg of Ulipristal acetate or a 
single dose of 1.5 mg of Levonorgestrel) or by placing an 
IUD within 5 days after unprotected intercourse; due to their 
lower cost, copper-bearing IUDs are more often employed. 
Their efficacy decreases as time passes and is variable: 
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the efficacy of progestin ranges from 54 to 99% within the 
first 72 h; Ulipristal acetate is three times more effective 
than Levonorgestrel. The IUD has an efficacy of 99% when 
placed within 120 h after unprotected intercourse [128–132].
The mechanism of action of high-dose progestin consists 
in thickening the cervical mucus and interfering with ovu-
lation: before the peak of LH (luteinizing hormone) they 
inhibit follicular maturation and prevent ovulation; UPA 
inhibits ovulation even after the onset of the LH peak, delay-
ing ovulation for at least 5 days. The side effects of high-
dose progestin are not different from those reported for POPs 
and other progestin formulations, although vomiting is more 
frequent. In case of vomiting within 2 h, the dose should 
be repeated, but the systematic use of anti-emetic drugs is 
not recommended. In spite of the high dosage of proges-
terone, this contraceptive does not contain oestrogens and 
can be considered reasonably safe in patients with kidney 
disease; however, it is not recommended in severe chronic 
liver disease. WHO does not warn against its use in any 
category, including the presence of deep venous thrombo-
sis. Frequent use of EC in women with MEC category 2, 3 
or 4 has to be discouraged; furthermore, a high dose of a 
steroid contraceptive can interact with the metabolisms of 
several drugs, including calcineurin inhibitors (see section 
on combined hormonal contraceptives). The oral emergency 
contraceptives do not prevent the implantation of a fertilized 
egg and do not affect an existing pregnancy. After taking 
an emergency contraceptive, patients often have menstrual 
irregularities [30, 128–132].
Surgical sterilization
– Surgical sterilization is the only non-reversible contra-
ceptive method (grade of evidence: high for the general 
population, no data for the specific categories related to 
CKD patients).
– The main risks are those linked with the surgical pro-
cedure (grade of evidence: high for the general popula-
tion, no data for the specific categories related to CKD 
patients).
Surgical sterilization is the only non-reversible contracep-
tive method; it includes female surgical sterilization (tubal 
sterilization) and male surgical sterilisation (vasectomy). 
While it is the method least frequently used in Europe, steri-
lization is the contraceptive method most used by women 
elsewhere in the world, particularly women in China, India 
and the United States. Before 1978, surgical sterilization 
was illegal in Italy (Article 552/1930 of the Italian Criminal 
Table 9  Failure rates, advantages and disadvantages of barrier methods. Adapted from [121]
STD sexually transmitted disease
Method Image Advantages Disadvantages Failure rate* (%)
Male condom Little training needed; it is indicate for 
unexpected or occasional sex acts or in 
teenagers that are insecure about their 
bodies; inexpensive
Not reusable; it can reduce excitation and 
cause discomfort
2–15
Female condom Latex free; more suitable when used with 
a lubricant
More complicated insertion than male 
condom; training is necessary
5–21
Diaphragm Reusable; inexpensive Does not protect against STDs; must be 
inserted before intercourse; training is 
necessary; discomfort during intercourse; 
not always suitable for multiparas or 
women with prolapse; not latex free; the 
use of spermicides can irritate the vagina 
and induce vaginal infections
6–16
Cervical Cap Same as the diaphragm Same as the diaphragm 6–16
Sponge Same as the diaphragm Same as the diaphragm, but contains 
spermicide
9–16
1354 Journal of Nephrology (2020) 33:1343–1359
1 3
Code); since 1978, (Law 194/78. Article 22), an adult 
woman has been allowed to ask for tubal sterilization if the 
procedure is expected to provide a health or psychological, 
benefit. In 2018 6% of married women in Italy chose this 
method (Table 3) [30].
Female sterilization (salpingectomy) consists in the 
removal of the fallopian tubes or in their ligature (occlusion), 
and can be performed by laparoscopy or by laparotomy. The 
first procedure involves ligature of the tubes and removal of 
a small section; because of the possibility of spontaneous 
reopening of the tubes and failure of the procedure, even if 
correctly performed, and because of the evidence that ovar-
ian cancer often originates in the fimbriae of the fallopian 
tubes, the surgical technique generally used nowadays con-
sists in the removal of the tubes in their entirety, followed by 
histological analysis. Sometimes, generally during caesarean 
section, the removal of the tubes is technically difficult or not 
possible and in these cases occlusion is preferred.
WHO recommends caution in patients with kidney dis-
eases. In fact, sterilization bears the risks of infection and 
haemorrhage, not specifically linked to the procedure itself, 
but common in all types of abdominal surgery [28].
Abortion
– Abortion should not be considered a birth control proce-
dure, and should not be used as such (grade of evidence: 
high for the general population, no data for the specific 
categories related to CKD patients).
– Surgical abortion may impair subsequent fertility and 
involves the risks common to all surgical procedures 
(grade of evidence: high for the general population, no 
data for the specific categories related to CKD patients).
– There is limited evidence regarding the use of “medical”, 
drug-induced abortion in CKD patients, and although it 
is less invasive, the procedure cannot be considered to be 
safe for CKD patients (grade of evidence: no data for the 
specific categories related to CKD patients).
Abortion is defined as the spontaneous or provoked inter-
ruption of a pregnancy before the 180th day (23rd week) 
of gestation. According to this definition, abortion cannot 
be considered a contraceptive method, since conception has 
already occurred. We have included it in this review because 
it is an important item in reproductive health. Elective abor-
tion can be voluntary, when requested by a pregnant woman, 
or therapeutic, when indicated for clinical or psychological 
reasons. Abortion is a controversial question throughout the 
world and laws regulating voluntary termination of preg-
nancy vary between countries. In some developing countries 
abortion is illegal but unofficially practiced, with high risks 
for women’s health and lives. In Europe, abortion is illegal 
in Malta, San Marino and Vatican City. In Italy a 1978 law 
(194/1978) legalized voluntary abortion and since then abor-
tion without medical indication has been legal in the first 
90 days of pregnancy, while abortion for therapeutic reasons 
can be practiced after the 90th day if the pregnancy repre-
sents a serious hazard for the woman’s life or well-being 
[133–135].
The procedure can be medical or surgical.
The drugs used for medical termination of pregnancy are 
Mifepristone and Misoprostol. Limited data are available 
on the use of these drugs in patients with CKD. Mifepris-
tone is metabolized by the liver, leading to potential drug 
interactions, while Misoprostol is excreted by the kid-
neys. In patients with reduced clearance, this can lead to 
increased bioavailability and higher peak concentrations of 
Misoprostol. There is not yet enough data available to show 
that reducing doses is advisable, and clinical surveillance is 
needed in patients with severe CKD. Animal studies have 
shown a worsening in kidney function after Mifepristone, 
but data on CKD women are not available. We were able 
to find only one published case series of three women with 
CKD (stage 4 or 5) which reported no complications after 
taking medical abortifacients [136, 137]. Medication may be 
preferable to a surgical procedure (vacuum aspiration and/or 
curettage) for women who wish to become pregnant again, 
because interventions on the uterus can impair subsequent 
placentation, especially if repeated. A Cochrane meta-anal-
ysis has shown that a medical procedure in the first trimester 
of pregnancy is related to a longer duration of bleeding than 
a surgical procedure (OR 2.94, 95% CI 2.10–3.78), but the 
difference in total blood loss is not significant (OR 1.90, 95% 
CI 0.05–3.75); this could be relevant in patients with anae-
mia [137, 138]. Surgical procedures are considered to low 
complexity ones, but once more data regarding the preferred 
procedure in patients with CKD are not available.
Summary remarks
Pregnancy is a challenge in CKD, but its improved prob-
ability of success makes contraception another important 
challenge for CKD patients.
In the early CKD stages (stages 1–2–3a), in patients 
without hypertension or proteinuria (except in SLE + aPL), 
virtually all options are available. Particular care should be 
paid to an increase in or development of proteinuria in pre-
disposed patients and to the development of urinary tract 
infections, in particular when patients use spermicide or a 
vaginal ring.
The contraceptive pill should be avoided in every CKD 
stage in hypertensive patients and in patients in stages 3b–5, 
as well as in patients with pro-coagulatory status, including 
systemic diseases such as SLE, or nephrotic proteinuria. The 
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options in these cases include progestin-only contraceptives, 
which can, however, cause spotting (sometimes increased by 
heparin use in dialysis patients), intrauterine devices, barrier 
methods and surgical sterilization.
As previously mentioned, the use of spermicides and the 
vaginal ring should be prescribed and monitored with care in 
patients with recurrent urinary tract infections, while data on 
intrauterine devices suggest that the risk of pelvic infection 
is slightly higher after insertion; infection can be avoided by 
previous targeted treatment, ensuring aseptic insertion, and 
possible antibiotic prophylaxis.
Dialysis patients are not good candidates for the pill, and 
alternative solutions should be sought; given their reduced 
fertility, barrier methods or non-medicated intrauterine 
devices are possible alternatives, while no contraindica-
tions, besides spotting, exist for progestin-only contracep-
tive agents.
In kidney transplant patients the use of the pill should 
be limited to the few patients with normal kidney function, 
normotension and no proteinuria, while alternative solutions 
need to be sought in all the other cases. Barrier methods are 
limited by their lower efficacy, except for ideal use, and in 
the case of choice of non-medicated intrauterine devices, 
attention to insertion procedures is warranted. No contrain-
dications, except for spotting, exist for progestin-only birth 
control agents; however, due to potential pharmacologic 
interactions, the level of antirejection drugs (in particular 
calcineurin inhibitors, but also all the drugs metabolised 
in the cytochrome P450 pathway), should be carefully 
monitored.
While no formal contraindications exist for emergency 
progestin use, this treatment should not be routinely used 
in patients with occasional intercourse, and the risk of 
pharmacologic interactions should be borne in mind (in 
particular with calcineurin inhibitors).
Abortion is not, and should never be used as a means 
of birth control. It should be avoided whenever possible in 
all CKD women, in whom the physical and psychological 
balance between low fertility and unwanted pregnancy is 
particularly difficult. When a pregnancy needs to be inter-
rupted, the limited evidence available on the lack of side 
effects of “medical” abortion should be balanced against 
the potential advantage of avoiding invasive procedures 
that risk further reducing fertility. These challenges are 
summarized in Fig. 1, depicting a treatment flow-chart 
based on the current knowledge on birth control in CKD 
patients.
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Be careful in case of:
• Vaginal ring or spermicide in paents
with frequent uro-genital infecons
or immunodepression
• Placement of IUD in paents at
infecous risk, in order to prevent
inseron infecon
• POPs in paents with obesity
• CHCs in paents with proteinuria 
AVOID CHCs
ALL METHODS EXCEPT CHCs
Be careful in case of:
• Vaginal ring or spermicide in paents
with frequent uro-genital infecons or 
immunodepression
• Placement of IUD in paents at
infecous risk, in order to prevent
inseron infecon
• POPs in paents with obesity
Fig. 1  Flow chart on contraception in CKD patients. SLE systemic lupus erythematosus, aPL antiphospholipid antibodies, IUD intrauterine 
device, POP progestin-only pill, CHC combined hormonal contraceptive, CKD chronic kidney disease
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